Healthcare news Pancreatic Cancer Treatment Market | Page 2


The study suggests that exocrine cancer is by far the most common type of pancreatic cancer accounting
for more than 95% of the overall pancreatic cancer types

Among the treatment types, targeted therapy occupied the largest share since it is considered as the
most effective treatment option, which blocks the growth and spread of cancer cells without damaging
healthy cells

North America dominated the segment with the largest revenue share in 2015 due to high adoption rate
of advanced treatment options and highly developed healthcare infrastructure

Asia Pacific is anticipated to show a significant growth during the forecast period, mainly due to
increasing government initiatives, growing awareness regarding the treatment options for pancreatic
cancer, and the availability of highly sophisticated medical infrastructure for effective treatment

Some of the major companies operating in this market are, but are not limited to, Eli Lilly and Company;
Celgene Corporation; F. Hoffmann-La Roche AG; Amgen, Inc.; Novartis AG; PharmaCyte Biotech, Inc.;
Clovis Oncology; Teva Pharmaceutical Industries Ltd.; Merck & Co., Inc.; and Pfizer, Inc.
Grand View Research has segmented the pancreatic cancer treatment market on the basis of affected region,
treatment, and region:
Pancreatic Cancer Treatment Affected Region Outlook (Revenue, USD Million, 2014 - 2025)
 Exocrine
 Endocrine
Pancreatic Cancer Treatment Outlook (Revenue, USD Million, 2014 - 2025)
 Chemotherapy
 Targeted Therapy
 Others
Pancreatic Cancer Treatment Regional Outlook (Revenue, USD Million, 2014 - 2025)

North America
Follow Us: